BD5279248
Trimetrexate , 98+% , 52128-35-5
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB776.80 | In Stock |
|
| 5mg | RMB1746.40 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 215-217 °C |
| Boiling point: | 647.0±65.0 °C(Predicted) |
| Density | 1.305±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C(protect from light) |
| solubility | DMSO : ≥ 61.5 mg/mL (166.48 mM) |
| form | Solid |
| pka | 8.09±0.30(Predicted) |
| color | Light yellow to green yellow |
Description and Uses
Trimetrexate (TMQ) has been approved for the treatment of Pneumocystis carinii in patients with AIDS and also exhibits antiprotozoal activity against Trypanosoma cruzi . The drug is available as a single-ingredient medication, but it can be administered along with folinic acid in much the same way that methotrexate is administered with calcium leucovorin in cancer chemotherapy. Trimetrexate is a derivative of methotrexate.
Antineoplastic.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| Hazardous Substances Data | 52128-35-5(Hazardous Substances Data) |
